Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1272971-35-3

Post Buying Request

1272971-35-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1272971-35-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1272971-35-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,2,9,7 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1272971-35:
(9*1)+(8*2)+(7*7)+(6*2)+(5*9)+(4*7)+(3*1)+(2*3)+(1*5)=173
173 % 10 = 3
So 1272971-35-3 is a valid CAS Registry Number.

1272971-35-3Relevant articles and documents

Discovery of the first C -nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients

Cho, Aesop,Zhang, Lijun,Xu, Jie,Lee, Rick,Butler, Thomas,Metobo, Sammy,Aktoudianakis, Vangelis,Lew, Willard,Ye, Hong,Clarke, Michael,Doerffler, Edward,Byun, Daniel,Wang, Ting,Babusis, Darius,Carey, Anne C.,German, Polina,Sauer, Dorothea,Zhong, Weidong,Rossi, Stephen,Fenaux, Martijn,McHutchison, John G.,Perry, Jason,Feng, Joy,Ray, Adrian S.,Kim, Choung U.

, p. 1812 - 1825 (2014/04/03)

Hepatitis C virus (HCV) infection presents an unmet medical need requiring more effective treatment options. Nucleoside inhibitors (NI) of HCV polymerase (NS5B) have demonstrated pan-genotypic activity and durable antiviral response in the clinic, and they are likely to become a key component of future treatment regimens. NI candidates that have entered clinical development thus far have all been N-nucleoside derivatives. Herein, we report the discovery of a C-nucleoside class of NS5B inhibitors. Exploration of adenosine analogs in this class identified 1′-cyano-2′-C-methyl 4-aza-7,9-dideaza adenosine as a potent and selective inhibitor of NS5B. A monophosphate prodrug approach afforded a series of compounds showing submicromolar activity in HCV replicon assays. Further pharmacokinetic optimization for sufficient oral absorption and liver triphosphate loading led to identification of a clinical development candidate GS-6620. In a phase I clinical study, the potential for potent activity was demonstrated but with high intra- and interpatient pharmacokinetic and pharmacodynamic variability.

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS

-

, (2011/04/19)

Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1272971-35-3